株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

PARP阻害剤の世界市場:規模、シェア、見通し、機会分析

PARP Inhibitor Market, by Drug Type (Niraparib, Olaparib, Rucaparib, and Talazoparib ), by Application, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis 2019 - 2027

発行 Coherent Market Insights 商品コード 914061
出版日 ページ情報 英文 147 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
PARP阻害剤の世界市場:規模、シェア、見通し、機会分析 PARP Inhibitor Market, by Drug Type (Niraparib, Olaparib, Rucaparib, and Talazoparib ), by Application, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis 2019 - 2027
出版日: 2019年09月25日 ページ情報: 英文 147 Pages
概要

当レポートは世界のPARP阻害剤市場について調査しており、市場機会や動向、成長および阻害要因、薬剤のタイプ・用途・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査の目的および前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の範囲

  • レポートの説明
    • 市場の定義および範囲
  • エグゼクティブサマリー
    • 薬物タイプ別
    • 用途別
    • 流通チャネル別
    • 地域別
  • Coherent Opportunity Map (COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • パイプライン分析
  • 規制シナリオ
  • 価格分析
  • 合併・買収のシナリオ
  • PEST分析
  • 疫学

第4章 市場分析:薬剤のタイプ別

  • イントロダクション
  • ニラパリブ(ゼジュラ)
  • オラパリブ(リンパルザ)
  • ルカパリブ(ルブラカ)
  • タラゾパリブ(タルゼンナ)

第5章 市場分析:用途別

  • イントロダクション
  • 卵巣がん
  • 乳がん

第6章 市場分析:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 市場分析:地域別

  • イントロダクション
  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋地域
  • 中東
  • アフリカ

第8章 競合情勢

  • ヒートマップ分析
  • 市場シェア分析
    • AstraZeneca Plc.,
    • Johnson & Johnson
    • GlaxoSmithKline plc.
    • Pfizer, Inc.
    • Clovis Oncology Inc.
    • AbbVie Inc.
    • Bristol - Myers Squibb
    • Merck KGaA
    • Genentech, Inc.
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • Karyopharm Therapeutics Inc.
    • 小野薬品工業株式会社
    • Jiangsu Hengrui Medicine Co., Ltd.
  • アナリストの見解

第9章 セクション

  • 参照資料
  • 調査方法
  • 当社について
目次

PARP inhibitors are drugs which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors are developed for treating several diseases, the most important one is cancer. Several types of cancers rely on PARP enzymes than regular cells, which makes these inhibitors an effective mode of treating cancers. PARP inhibitors are used to treat a subset of ovarian cancer. Currently, 3 PARP inhibitors have been approved for use in ovarian cancer patients who have undergone 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016, and Niraparib in 2017. Furthermore, several PARP inhibitors which are currently in later stages of development have shown promising results in recently released clinical trials data.

Market Dynamics

The global PARP inhibitors market is driven by product developments, increasing number of positive results, as well as availability of novel therapies in the market. Companies such as Pfizer, AstraZeneca and Tesaro, Inc. have a robust pipeline of PARP inhibitors and several ongoing trials of products are scheduled to be completed by 2022. These factors are expected to propel growth of the market over the forecast period. However, side effects associated with the drugs and drug resistance among patients are some of the factors that are expected to hamper the market growth.

Key features of the study:

  • This report provides in-depth analysis of the global PARP inhibitor market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019-2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global PARP inhibitor market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Sierra Oncology, Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market

Detailed Segmentation:

  • Global PARP inhibitor Market, By Drug Type:
    • Niraparib (Zejula)
    • Olaparib (Lynparza)
    • Rucaparib (Rubraca)
    • Talazoparib (Talzenna)
  • Global PARP inhibitor Market, By Application:
    • Ovarian Cancer
    • Breast Cancer
  • Global PARP inhibitor Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global PARP inhibitor Market, By Region:
    • North America
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • AstraZeneca Plc.,*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
    • Johnson & Johnson
    • GlaxoSmithKline plc.
    • Pfizer, Inc.,
    • Clovis Oncology Inc.
    • AbbVie Inc.
    • Bristol - Myers Squibb
    • Merck KGaA
    • Genentech, Inc.
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • Karyopharm Therapeutics Inc.
    • Ono Pharmaceutical Co. Ltd.,
    • Jiangsu Hengrui Medicine Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Pipeline Analysis
  • Regulatory Scenario
  • Pricing Analysis
  • Merger and Acquisition Scenario
  • PEST Analysis
  • Epidemiology

4. Global PARP Inhibitor Market, By Drug Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Niraparib (Zejula)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Olaparib (Lynparza)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Rucaparib (Rubraca)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Talazoparib (Talzenna)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

5. Global PARP Inhibitor Market, By Application, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global PARP Inhibitor Market, By Distribution Channel, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global PARP Inhibitor Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • AstraZeneca Plc.,*
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Clovis Oncology Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol - Myers Squibb
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Genentech, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Repare Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sierra Oncology, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Karyopharm Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ono Pharmaceutical Co. Ltd.,
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top